These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 33858976)

  • 1. Effects of Denosumab in Japanese Patients With Rheumatoid Arthritis Treated With Conventional Antirheumatic Drugs: 36-month Extension of a Phase III Study.
    Tanaka Y; Takeuchi T; Soen S; Yamanaka H; Yoneda T; Tanaka S; Nitta T; Okubo N; Genant HK; van der Heijde D
    J Rheumatol; 2021 Nov; 48(11):1663-1671. PubMed ID: 33858976
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identifying the preferable rheumatoid arthritis subgroups for intervention with the anti-RANKL antibody denosumab to reduce progression of joint destruction.
    Tanaka Y; Soen S; Ishiguro N; Yamanaka H; Yoneda T; Tanaka S; Ohira T; Nitta T; Okubo N; Genant H; van der Heijde D; Takeuchi T
    RMD Open; 2020 Jul; 6(2):. PubMed ID: 32732353
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of the anti-RANKL antibody denosumab on joint structural damage in patients with rheumatoid arthritis treated with conventional synthetic disease-modifying antirheumatic drugs (DESIRABLE study): a randomised, double-blind, placebo-controlled phase 3 trial.
    Takeuchi T; Tanaka Y; Soen S; Yamanaka H; Yoneda T; Tanaka S; Nitta T; Okubo N; Genant HK; van der Heijde D
    Ann Rheum Dis; 2019 Jul; 78(7):899-907. PubMed ID: 31036625
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of denosumab on Japanese patients with rheumatoid arthritis: a dose-response study of AMG 162 (Denosumab) in patients with RheumatoId arthritis on methotrexate to Validate inhibitory effect on bone Erosion (DRIVE)-a 12-month, multicentre, randomised, double-blind, placebo-controlled, phase II clinical trial.
    Takeuchi T; Tanaka Y; Ishiguro N; Yamanaka H; Yoneda T; Ohira T; Okubo N; Genant HK; van der Heijde D
    Ann Rheum Dis; 2016 Jun; 75(6):983-90. PubMed ID: 26585988
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of denosumab with regard to bone destruction in prognostic subgroups of Japanese rheumatoid arthritis patients from the phase II DRIVE study.
    Ishiguro N; Tanaka Y; Yamanaka H; Yoneda T; Ohira T; Okubo N; Genant HK; van der Heijde D; Takeuchi T
    Rheumatology (Oxford); 2019 Jun; 58(6):997-1005. PubMed ID: 30602032
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial.
    Miller PD; Bolognese MA; Lewiecki EM; McClung MR; Ding B; Austin M; Liu Y; San Martin J
    Bone; 2008 Aug; 43(2):222-229. PubMed ID: 18539106
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of 24 Months of Treatment With Romosozumab Followed by 12 Months of Denosumab or Placebo in Postmenopausal Women With Low Bone Mineral Density: A Randomized, Double-Blind, Phase 2, Parallel Group Study.
    McClung MR; Brown JP; Diez-Perez A; Resch H; Caminis J; Meisner P; Bolognese MA; Goemaere S; Bone HG; Zanchetta JR; Maddox J; Bray S; Grauer A
    J Bone Miner Res; 2018 Aug; 33(8):1397-1406. PubMed ID: 29694685
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative study of the inhibitory effect on bone erosion progression with denosumab treatment and conventional treatment in rheumatoid arthritis patients: study protocol for an open-label randomized controlled trial by HR-pQCT.
    Iwamoto N; Sato S; Sumiyoshi R; Chiba K; Miyamoto N; Arinaga K; Kobayashi M; Yamamoto H; Osaki M; Kawakami A
    Trials; 2019 Aug; 20(1):494. PubMed ID: 31409388
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, phase II clinical trial.
    Cohen SB; Dore RK; Lane NE; Ory PA; Peterfy CG; Sharp JT; van der Heijde D; Zhou L; Tsuji W; Newmark R;
    Arthritis Rheum; 2008 May; 58(5):1299-309. PubMed ID: 18438830
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of denosumab switched from bisphosphonates in preventing joint destruction in postmenopausal rheumatoid arthritis patients with anti-cyclic citrullinated peptide antibodies.
    Mori Y; Izumiyama T; Kurishima H; Kamimura M; Baba K; Mori N; Itoi E
    J Orthop Surg Res; 2021 Feb; 16(1):107. PubMed ID: 33541393
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of RANKL inhibition on promoting healing of bone erosion in rheumatoid arthritis using HR-pQCT: a 2-year, randomised, double-blind, placebo-controlled trial.
    So H; Cheng IT; Lau SL; Chow E; Lam T; Hung VW; Li EK; Griffith JF; Lee VW; Shi L; Huang J; Kwok KY; Yim CW; Li TK; Lo V; Lee J; Lee JJ; Qin L; Tam LS
    Ann Rheum Dis; 2021 Aug; 80(8):981-988. PubMed ID: 33811034
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Denosumab Versus Risedronate in Glucocorticoid-Induced Osteoporosis: Final Results of a Twenty-Four-Month Randomized, Double-Blind, Double-Dummy Trial.
    Saag KG; Pannacciulli N; Geusens P; Adachi JD; Messina OD; Morales-Torres J; Emkey R; Butler PW; Yin X; Lems WF
    Arthritis Rheumatol; 2019 Jul; 71(7):1174-1184. PubMed ID: 30816640
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Efficacy of Denosumab in Patients With Rheumatoid Arthritis: A Systematic Review and Pooled Analysis of Randomized or Matched Data.
    Hu Q; Zhong X; Tian H; Liao P
    Front Immunol; 2021; 12():799575. PubMed ID: 35069583
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of switching oral bisphosphonates to denosumab or daily teriparatide on the progression of radiographic joint destruction in patients with biologic-naïve rheumatoid arthritis.
    Ebina K; Hirao M; Hashimoto J; Matsuoka H; Iwahashi T; Chijimatsu R; Etani Y; Okamura G; Miyama A; Yoshikawa H
    Osteoporos Int; 2018 Jul; 29(7):1627-1636. PubMed ID: 29574517
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Denosumab significantly improves bone mineral density with or without bisphosphonate pre-treatment in osteoporosis with rheumatoid arthritis : Denosumab improves bone mineral density in osteoporosis with rheumatoid arthritis.
    Nakamura Y; Suzuki T; Kato H
    Arch Osteoporos; 2017 Sep; 12(1):80. PubMed ID: 28936606
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Effect of Discontinuing Denosumab in Patients With Rheumatoid Arthritis Treated With Glucocorticoids.
    Saag KG; McDermott MT; Adachi J; Lems W; Lane NE; Geusens P; Stad RK; Chen L; Huang S; Dore R; Cohen S
    Arthritis Rheumatol; 2022 Apr; 74(4):604-611. PubMed ID: 34535967
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass.
    Bone HG; Bolognese MA; Yuen CK; Kendler DL; Miller PD; Yang YC; Grazette L; San Martin J; Gallagher JC
    J Clin Endocrinol Metab; 2011 Apr; 96(4):972-80. PubMed ID: 21289258
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of denosumab on bone mineral density and bone turnover in patients with rheumatoid arthritis receiving concurrent glucocorticoids or bisphosphonates.
    Dore RK; Cohen SB; Lane NE; Palmer W; Shergy W; Zhou L; Wang H; Tsuji W; Newmark R;
    Ann Rheum Dis; 2010 May; 69(5):872-5. PubMed ID: 19734132
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of denosumab treatment on bone mineral density and joint destruction in patients with rheumatoid arthritis.
    Mochizuki T; Yano K; Ikari K; Kawakami K; Hiroshima R; Koenuma N; Ishibashi M; Momohara S
    J Bone Miner Metab; 2018 Jul; 36(4):431-438. PubMed ID: 28681148
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Three-year denosumab treatment in postmenopausal Japanese women and men with osteoporosis: results from a 1-year open-label extension of the Denosumab Fracture Intervention Randomized Placebo Controlled Trial (DIRECT).
    Sugimoto T; Matsumoto T; Hosoi T; Miki T; Gorai I; Yoshikawa H; Tanaka Y; Tanaka S; Fukunaga M; Sone T; Nakano T; Ito M; Matsui S; Yoneda T; Takami H; Watanabe K; Osakabe T; Okubo N; Shiraki M; Nakamura T
    Osteoporos Int; 2015 Feb; 26(2):765-74. PubMed ID: 25403903
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.